CohortGen 1 = 48 weeks; Gen 2/3 = 24, 32, 36 or 48 weeks according to viral responseKarlstrom et al

CohortGen 1 = 48 weeks; Gen 2/3 = 24, 32, 36 or 48 weeks according to viral responseKarlstrom et al 2008 Prospective cohortKieran et alRetrospective cohortOutcomes of Patients Co-Infected with HCV and HIVLaufer et alProspective cohortTable 1. Cont.MedChemExpress JWH-133 Patient Characteristics Study setting Genotype NS 2/3:100 42.9 395 (92?500) Median (range) 87.9 PEG-IFN 25033180 67.3 432 Mean NS PEG-IFN Concurrent HAART Brazil Spain 58 44 (27?7) Median (range) 42 (40?5) Median (range) 44 (41?6) 87 IVDU; 3 MSM; Median (IQR) 8 WSM NS 39 (36?3) 19 IVDU Median (IQR) 34 (17?0) Median (range) 15 IVDU; 7 blood products; 15 other or unknown 462 IVDU 1/4:65 ; 2/3:35 1/4:59.5 ; 2/3:40.5 NS 55.9 1/4:89.7 ; 2/3:10.3 52.9 19 prisoners 1/4:78.9 ; 2/3:21.1 NS 1/4:45.9 ; 2/3:54.1 74.5 430 (321.5?67); Median (IQR) 584 (490?96); Median (IQR) ,200 = 2; 200?50 = 15; .350 = 12 481 (222?169); Median (range) 68 CD4#250 = 39 patients; CD4.250 = 503 patients 1/4:51.5 ; 2/3:48.5 52 400 (270?10) Median (IQR) 98 87 IVDU 1/4:68.0 ; 2/3:32 78.5 NS 95.9 47 IVDU 59 42 (69) Mean (SD) NS Sample size Age Risk factor for HCV acquisition Advanced CD4 count liver damage at baseline at baseline (cells/mL) HCV treatment: pegylated (PEG) or standard (STD) interferon (IFN) WB RBV FD RBV HCV treatment: fixed-dose (FD) or weight-based (WB) buy Pluripotin Ribavarin Duration of (RBV) HCV treatment All 48 weeks Continue 20 weeks after undetectable serum RNA-HCV PEG-IFN WB RBV Spain 97 Italy 98 PEG-IFN plus RBV 79 58.6 PEG-IFN STD or PEG-IFN 64.9 PEG-IFN WB RBV 48 or 72 weeks, `according to genotype’ Mix of WB and FD RBV 6 RBV (dosing NS) WB RBV NS NS USA USA 29 19 Belgium 37 All 52 weeks Spain 542 82.7 PEG-IFN WB RBV Gen 1 or 4 = 48 weeks; Gen 2 or 3 = 24 or 48 weeks 71.9 PEG-IFN Canada 64 44 (39?0) 33 IVDU; 27 MSM Median (IQR) Italy Spain and Germany 521 17 36 (27?7) 17 IVDU Mean (range) 42 (39?6) 391 IVDU Median (IQR) 1/4:64.8 ; 2/3:35.2 1/4:70 ; 2/3:30 NS 39.5 445 (144) Mean (SD) 483 (355?65) Median (IQR) 94.1 ?STD-IFN PEG-IFN WB RBV WB RBV All 24 weeksStudyStudy CharacteristicsStudy designLerias de Almeida et alRetrospective cohortLopez-Cortes et alProspective cohortMacias et alProspective cohortGen 1 or 4 = 48 or 72 weeks; Gen 2 or 3 = 24 or 48 weeksMarchetti et al 2012 Retrospective cohortMaru et alRetrospective cohortMehta et alRetrospective cohortMichielsen et al 2009 Prospective cohortMira et alProspective cohortMurray et alRetrospective cohortMix of WB and FD Gen 1 = 48 weeks; RBV Gen 2/3 = 24 weeks (with potential to continue)Nasti et alProspective cohortOutcomes of Patients Co-Infected with HCV and HIVNeukam et alProspective cohortGen 1 or 4 = 48 or 72 weeks; Gen 2 or 3 = 24 weeks (when RVR achieved)Table 1. Cont.Patient Characteristics Study setting Genotype 1/4:60 ; 2/3:40 NS NS 524 (216?902) Mean (range) NS PEG-IFN NS 444 Mean 68.6 PEG-IFN Concurrent HAART France Germany 109 45 (29?8) NS Mean (range) 35 41 (68) Mean NS (SD) Sample size Age Risk factor for HCV acquisition Advanced CD4 count liver damage at baseline at baseline (cells/mL) HCV treatment: pegylated (PEG) or standard (STD) interferon (IFN) WB RBV RBV `according to current guidelines’ PEG or STD IFN FD RBV HCV treatment: fixed-dose (FD) or weight-based (WB) Ribavarin Duration of (RBV) HCV treatment All 48 weeks 24 or 48 weeks `according to current guidelines’ France 62 36 (34?0) 49 IVDU; 13 other Median (IQR) 43 (68) Mean (SD) 37 (68) Mean (SD) 41 (66.7) Mean (SD) NS NS 1/4:42.1 ; 2/3:57.9 18.2 32 IVDU; 4 WSM 1/4:48.8 ;.CohortGen 1 = 48 weeks; Gen 2/3 = 24, 32, 36 or 48 weeks according to viral responseKarlstrom et al 2008 Prospective cohortKieran et alRetrospective cohortOutcomes of Patients Co-Infected with HCV and HIVLaufer et alProspective cohortTable 1. Cont.Patient Characteristics Study setting Genotype NS 2/3:100 42.9 395 (92?500) Median (range) 87.9 PEG-IFN 25033180 67.3 432 Mean NS PEG-IFN Concurrent HAART Brazil Spain 58 44 (27?7) Median (range) 42 (40?5) Median (range) 44 (41?6) 87 IVDU; 3 MSM; Median (IQR) 8 WSM NS 39 (36?3) 19 IVDU Median (IQR) 34 (17?0) Median (range) 15 IVDU; 7 blood products; 15 other or unknown 462 IVDU 1/4:65 ; 2/3:35 1/4:59.5 ; 2/3:40.5 NS 55.9 1/4:89.7 ; 2/3:10.3 52.9 19 prisoners 1/4:78.9 ; 2/3:21.1 NS 1/4:45.9 ; 2/3:54.1 74.5 430 (321.5?67); Median (IQR) 584 (490?96); Median (IQR) ,200 = 2; 200?50 = 15; .350 = 12 481 (222?169); Median (range) 68 CD4#250 = 39 patients; CD4.250 = 503 patients 1/4:51.5 ; 2/3:48.5 52 400 (270?10) Median (IQR) 98 87 IVDU 1/4:68.0 ; 2/3:32 78.5 NS 95.9 47 IVDU 59 42 (69) Mean (SD) NS Sample size Age Risk factor for HCV acquisition Advanced CD4 count liver damage at baseline at baseline (cells/mL) HCV treatment: pegylated (PEG) or standard (STD) interferon (IFN) WB RBV FD RBV HCV treatment: fixed-dose (FD) or weight-based (WB) Ribavarin Duration of (RBV) HCV treatment All 48 weeks Continue 20 weeks after undetectable serum RNA-HCV PEG-IFN WB RBV Spain 97 Italy 98 PEG-IFN plus RBV 79 58.6 PEG-IFN STD or PEG-IFN 64.9 PEG-IFN WB RBV 48 or 72 weeks, `according to genotype’ Mix of WB and FD RBV 6 RBV (dosing NS) WB RBV NS NS USA USA 29 19 Belgium 37 All 52 weeks Spain 542 82.7 PEG-IFN WB RBV Gen 1 or 4 = 48 weeks; Gen 2 or 3 = 24 or 48 weeks 71.9 PEG-IFN Canada 64 44 (39?0) 33 IVDU; 27 MSM Median (IQR) Italy Spain and Germany 521 17 36 (27?7) 17 IVDU Mean (range) 42 (39?6) 391 IVDU Median (IQR) 1/4:64.8 ; 2/3:35.2 1/4:70 ; 2/3:30 NS 39.5 445 (144) Mean (SD) 483 (355?65) Median (IQR) 94.1 ?STD-IFN PEG-IFN WB RBV WB RBV All 24 weeksStudyStudy CharacteristicsStudy designLerias de Almeida et alRetrospective cohortLopez-Cortes et alProspective cohortMacias et alProspective cohortGen 1 or 4 = 48 or 72 weeks; Gen 2 or 3 = 24 or 48 weeksMarchetti et al 2012 Retrospective cohortMaru et alRetrospective cohortMehta et alRetrospective cohortMichielsen et al 2009 Prospective cohortMira et alProspective cohortMurray et alRetrospective cohortMix of WB and FD Gen 1 = 48 weeks; RBV Gen 2/3 = 24 weeks (with potential to continue)Nasti et alProspective cohortOutcomes of Patients Co-Infected with HCV and HIVNeukam et alProspective cohortGen 1 or 4 = 48 or 72 weeks; Gen 2 or 3 = 24 weeks (when RVR achieved)Table 1. Cont.Patient Characteristics Study setting Genotype 1/4:60 ; 2/3:40 NS NS 524 (216?902) Mean (range) NS PEG-IFN NS 444 Mean 68.6 PEG-IFN Concurrent HAART France Germany 109 45 (29?8) NS Mean (range) 35 41 (68) Mean NS (SD) Sample size Age Risk factor for HCV acquisition Advanced CD4 count liver damage at baseline at baseline (cells/mL) HCV treatment: pegylated (PEG) or standard (STD) interferon (IFN) WB RBV RBV `according to current guidelines’ PEG or STD IFN FD RBV HCV treatment: fixed-dose (FD) or weight-based (WB) Ribavarin Duration of (RBV) HCV treatment All 48 weeks 24 or 48 weeks `according to current guidelines’ France 62 36 (34?0) 49 IVDU; 13 other Median (IQR) 43 (68) Mean (SD) 37 (68) Mean (SD) 41 (66.7) Mean (SD) NS NS 1/4:42.1 ; 2/3:57.9 18.2 32 IVDU; 4 WSM 1/4:48.8 ;.